StemCells Inc. (STEM)
-NasdaqCM 1.87 
0.01(0.54%) 4:00PM EDT
| Prev Close: | 1.86 |
|---|
| Open: | 1.88 |
|---|
| Bid: | 1.85 x 1000 |
|---|
| Ask: | 1.89 x 1100 |
|---|
| 1y Target Est: | 3.31 |
|---|
| Beta: | 2.05 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.82 - 1.89 |
|---|
| 52wk Range: | 0.59 - 2.67 |
|---|
| Volume: | 294,382 |
|---|
| Avg Vol (3m): | 315,079 |
|---|
| Market Cap: | 71.55M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.76 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cloning: A Stem Cell Revolution?at Motley Fool(Sun, May 19)
- STEMCELLS INC FinancialsEDGAR Online Financials(Fri, May 17)
- STEMCELLS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- StemCells, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Thu, May 9)
- StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business UpdateGlobeNewswire(Thu, May 9)
- STEMCELLS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 9)
- StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business UpdateGlobeNewswire(Tue, May 7)
- StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Companyat Seeking Alpha(Thu, May 2)
- StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular DegenerationGlobeNewswire(Thu, Apr 18)
- Investing In The Stem Cell Sector: An Overviewat Seeking Alpha(Wed, Apr 17)
- StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New YorkGlobeNewswire(Mon, Apr 15)
- 3 Healthcare Stock Stories for Thursday Enjoymentat Wall St. Cheat Sheet(Thu, Apr 11)
- StemCells, Inc. Enters Agreement to Receive $19.3 Million From California Institute for Regenerative Medicine to Help Fund IND for Alzheimer's DiseaseGlobeNewswire(Thu, Apr 11)
- STEMCELLS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial ObligatiEDGAR Online(Thu, Apr 11)
- 4 Healthcare Stock Stories for Midweek Investment Wellnessat Wall St. Cheat Sheet(Wed, Apr 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 70.61 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.64 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.16 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States.
View More